Home > Boards > US Listed > Biotechs >

Idera Pharmaceuticals, Inc. (IDRA)

Add IDRA Price Alert      Hide Sticky   Hide Intro
Moderator: Cbdpotential
Search This Board: 
Last Post: 2/16/2018 2:50:01 PM - Followers: 151 - Board type: Free - Posts Today: 0

The Company has created DNA-based compounds that in preclinical studies act as antagonists of TLR7 and TLR9, such as IMO-3100, or as antagonists of TLRs 7, 8, and 9, such as IMO-8400. The Company is developing IMO-3100, an antagonist of TLR7 and TLR9, for the treatment of psoriasis. It has selected IMO-8400, an antagonist of TLRs 7, 8, and 9, for development in the treatment of autoimmune diseases, with lupus as the initial disease indication. IMO-2055, a TLR9 agonist, is its lead drug candidate for the treatment of cancer. Clinical trials of IMO-2055 completed by the Company or by Merck KGaA include four Phase I clinical trials, of which two were in healthy subjects and two were in refractory cancer patients, and one Phase II clinical trial. The Phase II clinical trial was a monotherapy trial of IMO-2055 in patients with metastatic or recurrent clear cell renal cancer.

In preclinical animal models, the Company TLR7, 8, and 9 agonists have shown adjuvant activity when combined with various types of antigens. It has designed and created a new class of molecules to inhibit gene expression. These gene silencing oligonucleotides, which it refer to as GSOs, are nucleic acid-based and represent a novel approach to selectively, silence gene expression. It is actively engaged in preclinical research with its GSOs that is designed to explore their potential as research reagents and therapeutic agents. In addition to the Company’s clinical programs in autoimmune and inflammatory diseases and in cancer, it has identified TLR drug candidates for applications in the treatment of infectious diseases, respiratory diseases and hematological malignancies, and TLR3 agonists for use as vaccine adjuvants.

IMO-2125, a synthetic DNA-based TLR9 agonist, is its lead candidate for the treatment of chronic hepatitis C virus (HCV), infection. The Company conducted two Phase I clinical trials of IMO-2125 in patients with chronic HCV infection, one in patients with HCV who had not responded to prior treatment and one in combination with ribavirin, an antiviral medication approved for use in combination with interferon-alpha in the treatment of HCV infection, in treatment-naive patients with genotype 1 chronic HCV infection. In addition to the use of TLR9 agonists in oncology applications, it selected IMO-4200 as a lead TLR7 and TLR8 agonist candidate for the treatment of hematological cancers. Its TLR9 agonists are designed to induce immune responses that could be useful in restoring immune system balance. IMO-2134 is its lead TLR9 agonist for asthma and allergies. In addition to use of TLR7, 8, and 9 agonists as vaccine adjuvants, it also has created TLR3 agonists for potential use as vaccine adjuvants.

The Company competes with Dynavax Technologies Corporation, GlaxoSmithKline plc., Pfizer, Inc., VentiRx Pharmaceuticals., Novartis, Dynavax Technologies Corporation, VaxInnate, Inc., Intercell AG, Cytos Biotechnology AG and Celldex Therapeutics, Inc.



Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IDRA News: Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) 01/23/2018 06:04:04 AM
IDRA News: Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) 01/23/2018 06:04:03 AM
IDRA News: Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) 01/22/2018 04:21:41 PM
IDRA News: Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) 01/22/2018 04:21:16 PM
IDRA News: Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) 01/22/2018 04:20:50 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#3173   A very interesting read. Thanks for posting. Stockdoggy 02/16/18 02:50:01 PM
#3172   this is long but makes a lot of noretreat 02/16/18 01:58:41 PM
#3171   Up, down, up. BB's think it is time Citrati 02/16/18 10:58:06 AM
#3170   been trading heavily the past week. did noretreat 02/08/18 08:41:56 PM
#3169   Surprised no one has commented on a nice Citrati 02/07/18 12:23:08 AM
#3168   I hear you. I am not all in Citrati 02/05/18 03:01:46 PM
#3167   The question I need answered is "how sweet noretreat 02/05/18 02:45:59 PM
#3166   Yes, I believe it is certain, IMO. You Citrati 02/05/18 02:37:45 PM
#3165   When does the merger take place? Is noretreat 02/05/18 02:27:03 PM
#3164   Daily thinks the bottom could be in. See Citrati 02/05/18 10:45:30 AM
#3163   Article on TLR-9 eradicating tumors getting attention.... jaybe 02/03/18 12:21:47 PM
#3162   Anyone watching BCRX will note that it is Citrati 01/26/18 12:44:06 PM
#3161   looking pretty weak here....where is the bottom? noretreat 01/25/18 04:19:38 PM
#3160   Looks to me like it will form a Cbdpotential 01/24/18 02:42:36 PM
#3159   Weird but sweet deal looks like to me terry hallinan 01/23/18 01:31:45 PM
#3158   The deal has very nice potential synergy IMO. Citrati 01/23/18 10:04:19 AM
#3157   Looks like some traders dumped at the open noretreat 01/23/18 09:57:14 AM
#3156   IMO the drop was exacerbated by indecision which Citrati 01/23/18 09:43:29 AM
#3155   Been out of the IDRA loop since selling Farmmarket1 01/22/18 08:09:56 PM
#3154   I added on both dips today and think noretreat 01/22/18 04:01:58 PM
#3153   At the risk of sounding ignorant, but searching noviceinvestor08 01/22/18 03:52:49 PM
#3152   ambulance chase noretreat 01/22/18 03:52:43 PM
#3151   I am happy with the merger I bought youssef 01/22/18 02:28:40 PM
#3150   Idera Shareholders Upset Over Merger Bid - (via tedkov 01/22/18 01:37:18 PM
#3149   No, too slow. However, pre-clinical moves usually Citrati 01/22/18 12:24:43 PM
#3148   I think this is a decent entry point noretreat 01/22/18 12:12:22 PM
#3147   A good trade IMO. I will take some Citrati 01/22/18 11:47:22 AM
#3146   Might jump in at $1.50 willlbone 01/22/18 11:45:21 AM
#3145   i just jumped in (not real deep) ... noretreat 01/22/18 11:37:16 AM
#3144   Good buying opportunity here with the stock some Stockdoggy 01/22/18 10:54:26 AM
#3143   Slide presentation. Citrati 01/22/18 10:46:15 AM
#3142   Synergistic discovery engines highlighted by two distinct research Citrati 01/22/18 10:16:50 AM
#3141   I think you're right . This gives IDRA's monkeyfrog 01/22/18 09:39:04 AM
#3140   Vince being named CEO is pretty bullish IMO. Farmmarket1 01/22/18 09:36:09 AM
#3139   My guess is that the Baker Bros are Stockdoggy 01/22/18 09:33:24 AM
#3138   You are right on. BBrothers owns approximately 14million Citrati 01/22/18 09:08:16 AM
#3137   Since I own both companies my opinion will monkeyfrog 01/22/18 09:02:12 AM
#3136   BRIEF-Biocryst Pharma And Idera Pharma Sign Merger Agreement noretreat 01/22/18 08:58:16 AM
#3135 U Citrati 01/22/18 08:55:14 AM
#3134   I am holding my core position tight as well. Citrati 01/20/18 08:01:36 PM
#3133   No, keep talking. I am listening, just Stockdoggy 01/20/18 03:44:50 PM
#3132   Starting to think I am a single ghost Citrati 01/19/18 11:09:08 PM
#3131   Smacking against that 200day again. I might Citrati 01/19/18 03:04:17 PM
#3130   IDRA stuck under the weekly 200day. Sold the Citrati 01/18/18 12:50:11 PM
#3129   Next up is 2.51 and then potentially 2.74 Citrati 01/15/18 10:26:33 PM
#3128   IDRA looks to be clearing 2.30's now to Citrati 01/10/18 08:47:23 PM
#3127   3 year weekly has 1st PT to 200day Citrati 01/06/18 06:00:19 PM
#3126   Sold trading shares when 2.33 didn't hold. Just Citrati 01/05/18 12:40:37 PM
#3125   Given that they stated their current cash position Phantom Lord 01/05/18 11:29:10 AM
#3124   Latest News. Citrati 01/05/18 10:25:48 AM